22:58 · 10 āļāļĢāļāļŽāļēāļ„āļĄ 2023

BREAKING:Novavax on the wave after receiving $350 million for unused COVID shots📈

Novavax
āļŦāļļāđ‰āļ™
NVAX.US, Novavax Inc
-
-

Novavax's (NVAX.US) share price jumped more than 20% after the biotech company said Canada had agreed to pay $350 million for Covid vaccines that were previously due to be delivered. The settlement, in the case of NVAX, is significant because the company's management expressed doubts about its viability earlier in the year. 

According to the SEC filing, the Canadian government's payment will be made in two equal instalments in 2023. It is worth mentioning that the vaccines for Covid-19 are the company's only commercial product. 

The company's shares are currently testing the limitation formed by the 100-day exponential moving average (purple curve). Source: xStation 5

8 āļ•āļļāļĨāļēāļ„āļĄ 2025, 21:27

US OPEN: Wall Street āđ„āļĄāđˆāļŦāļ§āļąāđˆāļ™āļ•āđˆāļ­āļāļēāļĢāļ›āļīāļ”āļĢāļąāļāļšāļēāļĨ 📈ðŸ’ē

7 āļ•āļļāļĨāļēāļ„āļĄ 2025, 16:33

DE40: āļ•āļĨāļēāļ”āļĒāļļāđ‚āļĢāļ›āļĒāļąāļ‡āļ„āļ‡āļ­āļĒāļđāđˆāļ āļēāļĒāđƒāļ•āđ‰āđāļĢāļ‡āļāļ”āļ”āļąāļ™āļˆāļēāļāļ āļēāļ„āļ­āļļāļ•āļŠāļēāļŦāļāļĢāļĢāļĄāļ—āļĩāđˆāļ­āđˆāļ­āļ™āđāļ­āđāļĨāļ°āļ„āļ§āļēāļĄāļ§āļļāđˆāļ™āļ§āļēāļĒāļ—āļēāļ‡āļāļēāļĢāđ€āļĄāļ·āļ­āļ‡

7 āļ•āļļāļĨāļēāļ„āļĄ 2025, 08:56

āļ‚āđˆāļēāļ§āđ€āļ”āđˆāļ™āļ§āļąāļ™āļ™āļĩāđ‰

7 āļ•āļļāļĨāļēāļ„āļĄ 2025, 08:33

āļŦāļļāđ‰āļ™āđ€āļ”āđˆāļ™āļˆāļģāđ€āļ”āļ·āļ­āļ™: Meta āļˆāļ°āļ„āļ§āđ‰āļēāđāļŠāļĄāļ›āđŒāļāļēāļĢāđāļ‚āđˆāļ‡āļ‚āļąāļ™ AI āđ„āļ”āđ‰āļŦāļĢāļ·āļ­āđ„āļĄāđˆ? ðŸĪ–

āđ€āļ‚āđ‰āļēāļŠāļđāđˆāļ•āļĨāļēāļ”āļžāļĢāđ‰āļ­āļĄāļĨāļđāļāļ„āđ‰āļēāļ‚āļ­āļ‡ XTB Group āļāļ§āđˆāļē 1 700 000 āļĢāļēāļĒ

āļœāļĨāļīāļ•āļ āļąāļ“āļ‘āđŒāļ—āļēāļ‡āļāļēāļĢāđ€āļ‡āļīāļ™āļ—āļĩāđˆāđ€āļĢāļēāđƒāļŦāđ‰āļšāļĢāļīāļāļēāļĢāļĄāļĩāļ„āļ§āļēāļĄāđ€āļŠāļĩāđˆāļĒāļ‡ āđ€āļĻāļĐāļŦāļļāđ‰āļ™ (Fractional Shares) āđ€āļ›āđ‡āļ™āļœāļĨāļīāļ•āļ āļąāļ“āļ‘āđŒāļ—āļĩāđˆāđƒāļŦāđ‰āļšāļĢāļīāļāļēāļĢāļˆāļēāļ XTB āđāļŠāļ”āļ‡āļ–āļķāļ‡āļāļēāļĢāđ€āļ›āđ‡āļ™āđ€āļˆāđ‰āļēāļ‚āļ­āļ‡āļŦāļļāđ‰āļ™āļšāļēāļ‡āļŠāđˆāļ§āļ™āļŦāļĢāļ·āļ­ ETF āđ€āļĻāļĐāļŦāļļāđ‰āļ™āđ„āļĄāđˆāđƒāļŠāđˆāļœāļĨāļīāļ•āļ āļąāļ“āļ‘āđŒāļ—āļēāļ‡āļāļēāļĢāđ€āļ‡āļīāļ™āļ­āļīāļŠāļĢāļ° āļŠāļīāļ—āļ˜āļīāļ‚āļ­āļ‡āļœāļđāđ‰āļ–āļ·āļ­āļŦāļļāđ‰āļ™āļ­āļēāļˆāļ–āļđāļāļˆāļģāļāļąāļ”
āļ„āļ§āļēāļĄāļŠāļđāļāđ€āļŠāļĩāļĒāļŠāļēāļĄāļēāļĢāļ–āđ€āļāļīāļ™āļāļ§āđˆāļēāđ€āļ‡āļīāļ™āļ—āļĩāđˆāļāļēāļ